Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01366157
NCT01366157
Completed
Not Applicable

Investigation to Evaluate the Levels of Human Germinal-center-Associated Lymphoma (HGAL) Protein in Pediatric Hodgkin Lymphoma and Correlate With Early Response

Children's Oncology Group0 sites23 target enrollmentMay 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsLymphoma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lymphoma
Sponsor
Children's Oncology Group
Enrollment
23
Primary Endpoint
Variability of HGAL protein expression in pediatric patients with low-risk classical Hodgkin lymphoma (cHL)
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research trial is studying protein biomarker levels in tissue samples from young patients with low-risk Hodgkin lymphoma.

Detailed Description

OBJECTIVES: * To investigate the variability of expression of human geminal-center-associated lymphoma (HGAL) protein in pediatric low-risk Hodgkin lymphoma. * To assess the variability of HGAL staining between risk groups by comparing samples from subjects enrolled in the low-risk study AHOD0431 with subject samples enrolled in AHOD0031 for intermediate-risk classical Hodgkin Lymphoma (cHL). * To assess the variability of HGAL staining by evaluating a tissue array created from subjects with intermediate-risk cHL. * To correlate rapid or slow early-response in the intermediate-risk group with HGAL protein expression. OUTLINE: Paraffin-embedded tissue samples and tissue microarrays are analyzed for protein expression by IHC.

Registry
clinicaltrials.gov
Start Date
May 2011
End Date
May 2016
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Variability of HGAL protein expression in pediatric patients with low-risk classical Hodgkin lymphoma (cHL)

Variability of HGAL staining between low-risk and intermediate-risk pediatric patients with cHL

Variability of HGAL staining as assessed by tissue array in pediatric patients with intermediate-risk cHL

Correlation of rapid or slow early response in the intermediate-risk group with HGAL protein expression

Similar Trials

Completed
Not Applicable
S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313Breast Cancer
NCT00949013SWOG Cancer Research Network1,600
Unknown
Not Applicable
Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 TrialBreast Cancer
NCT01424865NSABP Foundation Inc1,874
Completed
Not Applicable
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid LeukemiaLeukemia
NCT00897936ECOG-ACRIN Cancer Research Group418
Completed
Phase 2
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal CancerColorectal Cancer
NCT00975897Medical Research Council3,240
Completed
Not Applicable
Protein Expression in Samples From Young Patients With RhabdomyosarcomaSarcoma
NCT01426945Children's Oncology Group77